ductal carcinoma in situ
PreludeDx DCIS Breast Cancer Test Helps Determine Radiation Therapy Benefits, Reduce Overtreatment
Premium
The test uses prognostic markers to group women based on their risk of 10-year recurrence of ductal carcinoma in situ.
PreludeDx Receives New York State Approval for DCIS Test
The company will now be able to market the test, which algorithmically weighs molecular markers and clinical information, in all 50 US states.
Clinical validation work suggests that the firm's DCISionRT test could be used to stratify patients who may benefit from radiation, in addition to being used as a diagnostic tool.